Fat Chance FDA Chastises Orexigen for Disclosing Interim Trial Data

Mar 4, 2015, 00:00 by Michael Croft

Pharmalot | The FDA has publicly chastised a drug maker for unexpectedly disclosing interim study data for a medicine in a filing with the U.S. Securities and Exchange Commission.

March 04, 2015 | The FDA has publicly chastised a drug maker for unexpectedly disclosing interim study data for a medicine in a filing with the U.S. Securities and Exchange Commission. Pharmalot